Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.
Quick Facts
What This Study Found
Tesamorelin decreased 13 circulating immune markers (chemokines, cytokines, T-cell molecules) and downregulated hepatic immune activation pathways in a 12-month randomized trial of 61 HIV patients with NAFLD.
Key Numbers
61 patients; 12 months; 92 biomarkers; 13 decreased (CCL3, CCL4, CCL13, IL8, IL-10, CSF-1, CD8A, CRTAM, GZMA, ADGRG1, ARG1, Gal-9, HGF); 0 increased; liver transcriptomics confirmed
How They Did This
Double-blind, randomized trial. 61 people with HIV and NAFLD received tesamorelin or placebo for 12 months. 92 immune biomarkers measured by proteomics. Gene set enrichment analysis on serial liver biopsies.
Why This Research Matters
Chronic immune activation in HIV accelerates liver disease, heart disease, and aging. Finding that a GHRH analog can dampen this activation opens a new therapeutic approach beyond traditional antiretroviral therapy.
What This Study Doesn't Tell Us
Small trial (61 patients). HIV population may not generalize to other groups. Proteomics approach measures many markers, increasing chance of false positives. Only NAFLD patients studied, not HIV patients without liver disease.
Trust & Context
- Original Title:
- Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.
- Published In:
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(4), 621-630 (2021)
- Authors:
- Stanley, Takara L(3), Fourman, Lindsay T, Wong, Lai Ping, Sadreyev, Ruslan, Billingsley, James M, Feldpausch, Meghan N, Zheng, Isabel, Pan, Chelsea S, Boutin, Autumn, Lee, Hang, Corey, Kathleen E, Torriani, Martin, Kleiner, David E, Chung, Raymond T, Hadigan, Colleen M, Grinspoon, Steven K
- Database ID:
- RPEP-05788
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05788APA
Stanley, Takara L; Fourman, Lindsay T; Wong, Lai Ping; Sadreyev, Ruslan; Billingsley, James M; Feldpausch, Meghan N; Zheng, Isabel; Pan, Chelsea S; Boutin, Autumn; Lee, Hang; Corey, Kathleen E; Torriani, Martin; Kleiner, David E; Chung, Raymond T; Hadigan, Colleen M; Grinspoon, Steven K. (2021). Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(4), 621-630. https://doi.org/10.1093/cid/ciab019
MLA
Stanley, Takara L, et al. "Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. https://doi.org/10.1093/cid/ciab019
RethinkPeptides
RethinkPeptides Research Database. "Growth Hormone Releasing Hormone Reduces Circulating Markers..." RPEP-05788. Retrieved from https://rethinkpeptides.com/research/stanley-2021-growth-hormone-releasing-hormone
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.